Gradientech to raise SEK 20M from Almi and other existing investors.

Gradientech AB, an Uppsala, Sweden0based life science company announced the clsoing of SEK 20M () in capital investment.

The money was provided by existing investors. In conjunction with the funding round, the Board is extended with Henrik Didner as new director.

The equity funding will be used for the continued market-driven design and development of the QuickMIC™ diagnostic system with the aim to initiate clinical validation during 2019. Gradientech has in total raised $4.5M during the last year in private equity funding.

Gradientech AB founded in 2009 and led by CEO Sara Thorslund, develops and provides microscale tools for live imaging of cell behavior in response to defined concentration gradients. The company is developing the in vitro diagnostic (IVD) QuickMIC system, a promising platform based on phenotypic bacteria growth analysis. The system is expected to become the most rapid solution for diagnosing appropriate antibiotic treatment of sepsis patients. Rapid antibiotic susceptibility testing is considered essential for increasing sepsis patient survival, especially in the global situation of increasing antibiotic resistance.